Peer-reviewed veterinary case report
Levagen+ reduces joint pain in dogs and cats in 6 weeks
By Briskey, David et al.·Published in Frontiers in veterinary science·2026·School of Human Movement and Nutrition Sciences, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Levagen+ (palmitoylethanolamide) alleviates joint pain and reduces the impact of joint pain in canines and felines: a double-blind, placebo-controlled, randomized clinical trial.
Plain-English summary
A group of dogs and cats with joint pain were given either Levagen+ (a fatty acid supplement) or a placebo for six weeks to see which helped relieve their discomfort. The results showed that 76% of the dogs taking Levagen+ felt better compared to only 40% of those on the placebo. Cats also showed improvements, particularly in their ability to jump up and down, and reported less pain at the two and six-week marks. Overall, Levagen+ was well tolerated and helped reduce joint pain in both dogs and cats.
People also search for: dog joint pain relief · cat joint pain treatment · Levagen+ for dogs and cats · fatty acid supplement for pets · how to help my dog jump again
Abstract
INTRODUCTION: This study assessed the effectiveness of Levagen+ (palmitoylethanolamide), a fatty acid amide and lipid mediator, for both the alleviation and impact of joint pain, in canines and felines. METHODS: This prospective double-blinded, randomized placebo-controlled study supplemented 50 canines and 50 felines experiencing joint pain daily for 6 weeks with either Levagen+ or a placebo taken orally. Efficacy was determined in canines using the Canine Brief Pain Index (CBPI) and in felines using the Feline Musculoskeletal Pain Index (FMPI), both completed by owners at baseline, week 2, week 4 and week 6. Data were analyzed with distribution-appropriate tests and a two-way repeated-measures ANOVA to assess group, time, and interaction effects across outcomes. RESULTS: In canines, significantly more were classified as successfully treated in the Levagen+ group compared to the placebo group (76% vs. 40%; < 0.05), with significant improvements in multiple pain and functional interference domains. In felines, significant between-group differences were observed for specific functional tasks [jumping up ( < 0.05), jumping down ( < 0.05)] and in scores for current pain [week 2 ( < 0.05) and week 6 ( < 0.05)]. Levagen+ was well tolerated in both species. DISCUSSION: These findings supported the hypothesis that Levagen+ reduces the impact of joint pain in companion animals.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41767672/